Studying the value of fractional exhaled Nitric Oxide and blood eosinophils as biomarkers in predicting which patients will suffer from more frequent asthma exacerbations, and evaluating the subsequent healthcare resource utilisation (Assessing RIsk of exAcerbation (ARIA))

First published 20/07/2017

Last updated 01/04/2024

EU PAS number:

EUPAS16891

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

121216 FeNO and Eosinophils in ICS-Treated Asthma_v1.3

English (1.19 MB - PDF) View document

Study results

No information provided.

Study report

2017_06_22_AUREA_final_report_1.2FIN

English (5.14 MB - PDF) View document

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

Studying the value of fractional exhaled Nitric Oxide and blood eosinophils as biomarkers in predicting which patients will suffer from more frequent asthma exacerbations, and evaluating the subsequent healthcare resource utilisation (Assessing RIsk of exAcerbation (ARIA))

Secondary tabs

Share this page